Targeting autophagy: A promising approach for the treatment of breast cancer brain metastases

Abstract

Patients with breast tumours that metastasise to the brain have limited treatment options and a very poor prognosis. More effective therapeutic strategies are desperately needed for this patient population. Recent evidence demonstrates that brain metastases arising from breast tumours display altered energy production that results in enhanced autophagy. Preclinical studies have shown that genetically or pharmacologically disrupting the autophagy pathway significantly decreases the brain metastatic burden, resulting in improved animal survival and increased sensitivity to lapatinib. These findings pave the way for the development of novel strategies targeting autophagy for breast cancer patients with brain metastatic disease.

Keywords

autophagy / brain metastasis / breast cancer / hydroxychloroquine / lapatinib

References

[1] Patel RR, Mehta MP. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res. 2007;13:1675-1683.

[2] Warrior S, Cohen-Nowak A, Kumthekar P. Modern management and diagnostics in HER2+ breast cancer with CNS metastasis. Cancers. 2023;15(11):2908.

[3] Nawrocki ST, Wang W, Carew JS. Autophagy: new insights into its roles in cancer progression and drug resistance. Cancers. 2020;12(10):3005.

[4] Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res. 2012;18:370-379.

[5] Nawrocki ST, Espitia CM, Espinoza MJC, et al. Inhibition of autophagy antagonizes breast cancer brain metastogenesis and augments the anticancer activity of lapatinib. Clin Transl Med. 2024;14:e1662.

[6] Chen EI, Hewel J, Krueger JS, et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 2007;67:1472-1486.

[7] Shinde A, Hardy SD, Kim D, et al. Spleen tyrosine kinase-mediated autophagy is required for epithelial-mesenchymal plasticity and metastasis in breast cancer. Cancer Res. 2019;79:1831-1843.

[8] Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14:64-71.

[9] Jones TM, Espitia C, Wang W, Nawrocki ST, Carew JS. Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies. Cancer Commun. 2019;39:72.

[10] Visconte V, Przychodzen B, Han Y, et al. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. Leukemia. 2017;31:505-510.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.